# The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants

> **NCT01021683** · — · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 203 (actual)

## Conditions studied

- Hematologic Neoplasms
- Neutropenia
- Fever

## Interventions

- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT01021683
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021683, "The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01021683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*